Pearl Steinzor

Deborah Doroshow, MD, PhD, an oncologist and historian, reflects on guiding patients through cancer care and how lessons from the past shape treatment today.

High-dose vitamin D₃ supplementation reduced diabetes risk by 19% in adults with prediabetes who carry specific vitamin D receptor gene variants.

Researchers found persistent and substantial delays between heart failure diagnosis and ATTR-CM identification.

Shara Bialo, MD, emphasizes the crucial role of school nurses in early detection of type 1 diabetes.

Loss of a partner or sibling during the pandemic was associated with heightened cardiovascular vulnerability, according to one study.

Experts dismantled the assumption that direct-to-patient is a universal affordability solution, offering manufacturers a practical framework for deciding which model is actually right.

Specialty pharmacies play a critical role in connecting patients with assistance programs to combat growing financial complexities.

At AXS26, leaders shared the hard-won organizational, strategic, and operational lessons from rounds 1, 2, and 3 of the Medicare Drug Price Negotiation Program.

Experts examine what is working in production, where the guardrails are being tested, and why the most transformative chapter of AI in health care hasn’t started yet.

The future of specialty pharmacy is not automation alone, but technology designed to assist patients through personalized support.

The entire commercial logic of the pharmaceutical industry’s patient engagement model is built for a moment that no longer exists, according to Chris Moose.

Policy and market access experts break down the compounding forces reshaping drug pricing, PBM regulation, and manufacturer strategy heading into the 2026 midterms.

The ECHO study raises timely questions about whether managed care coverage policies have kept pace with evolving evidence.

Fran Gregory, PharmD, MBA, explains why community providers can't go it alone—and how specialty pharmacy is stepping in to carry the load.

The DEA's 30th biannual collection event arrives April 25, 2026—here's what patients and clinicians need to know.

An analysis shows accelerated declines in processing speed, memory, and global cognition years before incident cardiovascular disease.

Teplizumab-mzwv is the first disease-modifying therapy available for children as young as 1 year diagnosed with presymptomatic type 1 diabetes.

Subgroup data show no reduction in cardiovascular death or myocardial infarction—and a potential signal of harm—in highly frail patients.

SPIRIT-HF reported neutral outcomes for spironolactone in HFpEF/HFmrEF, but ongoing analyses may clarify which patients benefit most.

A new industry report underscores the momentum—and the work ahead—as gene-, cell-, and tissue-based treatments move from academic health systems into community care.

The FDA is encouraging drug sponsors to pursue a new indication for testosterone replacement therapy.

A July 2026 advisory meeting will evaluate whether broader compounding access to peptides is justified despite concerns around safety, efficacy, and limited clinical evidence.

Real-world EHR study shows PREVENT equations deliver reliable CVD risk prediction despite missing data, guiding smarter outreach and recalibration.

A recent study identified persistent myocardial fibroblast activation in patients with heart failure with reduced ejection fraction, with distinct patterns by etiology.

John Barkett, MBA, discusses recent regulatory proposals to make massive health plan price files more usable.

Esketamine's monotherapy approval and new real-world data are forcing a reckoning for managed care.

A large cohort study across UK Biobank and All of Us finds RBM20 variants contribute to arrhythmogenic dilated cardiomyopathy.

Finerenone lowered cardiovascular death and HF events irrespective of coronary heart disease status but did not reduce atherothrombotic outcomes.

Vutrisiran not only slowed progression to advanced heart failure in patients with ATTR-CM but also reduced mortality and MACE among those who developed advanced disease.

Tirzepatide was associated with a significant reduction in a composite of major cardiovascular and kidney outcomes vs the GLP-1 agonist dulaglutide.